miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors
Yael Gothelf, Haggai Kaspi, Natalie Abramov, Revital Aricha, Yael Gothelf, Haggai Kaspi, Natalie Abramov, Revital Aricha
Abstract
Background: MSC-NTF cells are Mesenchymal Stromal Cells (MSC) induced to express high levels of neurotrophic factors (NTFs) using a culture-medium based approach. MSC-NTF cells have been successfully studied in clinical trials for Amyotrophic Lateral Sclerosis (ALS) patients. MicroRNAs (miRNA) are short non-coding RNA molecules that coordinate post-transcriptional regulation of multiple gene targets. The purpose of this study was to determine whether the miRNA profile could provide a tool for MSC-NTF cell characterization and to distinguish them from the matched MSC from which they are derived.
Methods: NTF secretion in the culture supernatant of MSC-NTF cells was evaluated by ELISA assays. The Agilent microarray miRNA platform was used for pairwise comparisons of MSC-NTF cells to MSC. The differentially expressed miRNAs and putative mRNA targets were validated using qPCR analyses.
Results: Principal component analysis revealed two distinct clusters based on cell type (MSC and MSC-NTFs). Nineteen miRNAs were found to be upregulated and 22 miRNAs were downregulated in MSC-NTF cells relative to the MSC cells of origin. Further validation of differentially expressed miRNAs confirmed that miR-3663 and miR-132 were increased 18.5- and 4.06-fold, respectively while hsa-miR-503 was reduced more than 15-fold, suggesting that miRNAs could form the basis of an MSC-NTF cell characterization assay. In an analysis of the miRNA mRNA targets, three mRNA targets of hsa-miR-132-3p (HN-1, RASA1 and KLH-L11) were found to be significantly downregulated.
Conclusions: We have demonstrated that MSC-NTF cells can be distinguished from their MSCs of origin by a unique miRNA expression profile.
Trial registration: Clinicaltrial.gov identifier NCT01777646 . Registered 12 December 2012.
Keywords: Amyotrophic Lateral Sclerosis; Mesenchymal Stromal Cells; MicroRNAs; Neurotrophic Factors.
Conflict of interest statement
Authors’ informationNot applicable.
Ethics approval and consent to participateALS patients were consented in accordance with the Helsinki declaration in the context of the phase 2a clinical trial
Consent for publicationNot applicable.
Competing interestsAuthors are Brainstorm Cell Therapeutics employees
Publisher’s NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
References
- Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7. doi: 10.1126/science.284.5411.143.
- Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13:392–402. doi: 10.1016/j.stem.2013.09.006.
- Gothelf Y, Abramov N, Harel A, et al. Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells. Clin Transl Med. 2014;3:21. doi: 10.1186/2001-1326-3-21.
- Petrou P, Gothelf Y, Argov Z, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016;73:337–44. doi: 10.1001/jamaneurol.2015.4321.
- Henderson CE. Role of neurotrophic factors in neuronal development. Curr Opin Neurobiol. 1996;6:64–70. doi: 10.1016/S0959-4388(96)80010-9.
- Bartus RT, Johnson EM., Jr Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: where have we been and what have we learned? Neurobiol Dis. 2017;97:156–68. doi: 10.1016/j.nbd.2016.03.027.
- Bartus RT, Johnson EM., Jr Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: where do we stand and where must we go next? Neurobiol Dis. 2017;97:169–78. doi: 10.1016/j.nbd.2016.03.026.
- Wang Y, Chen X, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014;15:1009–16. doi: 10.1038/ni.3002.
- Perets N, Segal-Gavish H, Gothelf Y, et al. Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism. Behav Brain Res. 2017;331:254–60. doi: 10.1016/j.bbr.2017.03.047.
- Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55. doi: 10.1016/S0140-6736(10)61156-7.
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97. doi: 10.1016/S0092-8674(04)00045-5.
- Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309:1519–24. doi: 10.1126/science.1111444.
- Lim LP, Glasner ME, Yekta S, et al. Vertebrate microRNA genes. Science. 2003;299:1540. doi: 10.1126/science.1080372.
- Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034. doi: 10.1186/gb-2002-3-7-research0034.
- Chamorro-Jorganes A, Araldi E, Penalva LO, et al. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol. 2011;31:2595–606. doi: 10.1161/ATVBAHA.111.236521.
- Yin Z, Zhao Y, Li H, et al. miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway. Aging (Albany NY) 2016;8:192–207. doi: 10.18632/aging.100876.
- Zhou B, Ma R, Si W, et al. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett. 2013;333:159–69. doi: 10.1016/j.canlet.2013.01.028.
- Edbauer D, Neilson JR, Foster KA, et al. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron. 2010;65:373–84. doi: 10.1016/j.neuron.2010.01.005.
- Magill ST, Cambronne XA, Luikart BW, et al. microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc Natl Acad Sci U S A. 2010;107:20382–7. doi: 10.1073/pnas.1015691107.
- Hancock ML, Preitner N, Quan J, et al. MicroRNA-132 is enriched in developing axons, locally regulates Rasa1 mRNA, and promotes axon extension. J Neurosci. 2014;34:66–78. doi: 10.1523/JNEUROSCI.3371-13.2014.
- Zujovic V, Luo D, Baker HV, et al. The facial motor nucleus transcriptional program in response to peripheral nerve injury identifies Hn1 as a regeneration-associated gene. J Neurosci Res. 2005;82:581–91. doi: 10.1002/jnr.20676.
- Zhang ZG, Chen WX, Wu YH, et al. MiR-132 prohibits proliferation, invasion, migration, and metastasis in breast cancer by targeting HN1. Biochem Biophys Res Commun. 2014;454:109–14. doi: 10.1016/j.bbrc.2014.10.049.
- Laughlin KM, Luo D, Liu C, et al. Hematopoietic- and neurologic-expressed sequence 1 (Hn1) depletion in B16.F10 melanoma cells promotes a differentiated phenotype that includes increased melanogenesis and cell cycle arrest. Differentiation. 2009;78:35–44. doi: 10.1016/j.diff.2009.04.001.
- Dhanoa BS, Cogliati T, Satish AG, et al. Update on the Kelch-like (KLHL) gene family. Hum Genomics. 2013;7:13. doi: 10.1186/1479-7364-7-13.
- Caporali A, Emanueli C. MicroRNA-503 and the extended microRNA-16 family in angiogenesis. Trends Cardiovasc Med. 2011;21:162–6. doi: 10.1016/j.tcm.2012.05.003.
- Sun Y, Xu J, Xu L, et al. MiR-503 promotes bone formation in distraction osteogenesis through suppressing Smurf1 expression. Sci Rep. 2017;7:409. doi: 10.1038/s41598-017-00466-4.
- Forrest AR, Kanamori-Katayama M, Tomaru Y, et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia. 2010;24:460–6. doi: 10.1038/leu.2009.246.
- Somel M, Liu X, Tang L, et al. MicroRNA-driven developmental remodeling in the brain distinguishes humans from other primates. PLoS Biol. 2011;9:e1001214. doi: 10.1371/journal.pbio.1001214.
- Yoshizuka M, Nakasa T, Kawanishi Y, et al. Inhibition of microRNA-222 expression accelerates bone healing with enhancement of osteogenesis, chondrogenesis, and angiogenesis in a rat refractory fracture model. J Orthop Sci. 2016;21:852–8. doi: 10.1016/j.jos.2016.07.021.
- Anand S, Majeti BK, Acevedo LM, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010;16:909–14. doi: 10.1038/nm.2186.
- Hu Z, Wang Y, Sun Z, et al. miRNA-132-3p inhibits osteoblast differentiation by targeting Ep300 in simulated microgravity. Sci Rep. 2015;5:18655. doi: 10.1038/srep18655.
- Wang N, Zhou Z, Wu T, et al. TNF-alpha-induced NF-kappaB activation upregulates microRNA-150-3p and inhibits osteogenesis of mesenchymal stem cells by targeting beta-catenin. Open Biol. 2016;6:150258. doi: 10.1098/rsob.150258.
- Zhang D, Zhao T, Ang HS, et al. AMD1 is essential for ESC self-renewal and is translationally down-regulated on differentiation to neural precursor cells. Genes Dev. 2012;26:461–73. doi: 10.1101/gad.182998.111.
- Farooqi AA, Fayyaz S, Shatynska-Mytsyk I, et al. Is miR-34a a Well-equipped swordsman to conquer temple of molecular oncology? Chem Biol Drug Des. 2016;87:321–34. doi: 10.1111/cbdd.12634.
- Guennewig B, Roos M, Dogar AM, et al. Synthetic pre-microRNAs reveal dual-strand activity of miR-34a on TNF-alpha. RNA. 2014;20:61–75. doi: 10.1261/rna.038968.113.
- Chen L, Holmstrom K, Qiu W, et al. MicroRNA-34a inhibits osteoblast differentiation and in vivo bone formation of human stromal stem cells. Stem Cells. 2014;32:902–12. doi: 10.1002/stem.1615.
Source: PubMed